Corteva, Inc. $CTVA Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its stake in Corteva, Inc. (NYSE:CTVAFree Report) by 17.9% during the third quarter, Holdings Channel.com reports. The fund owned 4,169,715 shares of the company’s stock after selling 908,319 shares during the period. JPMorgan Chase & Co.’s holdings in Corteva were worth $281,998,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. NORTHSTAR ASSET MANAGEMENT Co raised its position in Corteva by 2.2% in the second quarter. NORTHSTAR ASSET MANAGEMENT Co now owns 6,940 shares of the company’s stock valued at $517,000 after purchasing an additional 150 shares during the period. Empirical Finance LLC grew its stake in shares of Corteva by 0.6% in the second quarter. Empirical Finance LLC now owns 24,935 shares of the company’s stock valued at $1,858,000 after buying an additional 153 shares in the last quarter. Carnegie Investment Counsel raised its holdings in shares of Corteva by 3.0% in the 2nd quarter. Carnegie Investment Counsel now owns 5,607 shares of the company’s stock valued at $418,000 after buying an additional 164 shares during the period. United Community Bank lifted its stake in Corteva by 10.5% during the 3rd quarter. United Community Bank now owns 1,849 shares of the company’s stock worth $125,000 after acquiring an additional 176 shares in the last quarter. Finally, Curat Global LLC boosted its holdings in Corteva by 93.7% during the 2nd quarter. Curat Global LLC now owns 370 shares of the company’s stock valued at $28,000 after acquiring an additional 179 shares during the period. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Corteva Stock Up 0.5%

Corteva stock opened at $77.00 on Friday. The stock has a market cap of $51.78 billion, a PE ratio of 48.74, a P/E/G ratio of 2.61 and a beta of 0.75. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.96. The stock’s fifty day moving average is $70.51 and its two-hundred day moving average is $68.57. Corteva, Inc. has a 1-year low of $53.40 and a 1-year high of $77.41.

Corteva (NYSE:CTVAGet Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The business had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same period in the prior year, the firm posted $0.32 EPS. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, sell-side analysts expect that Corteva, Inc. will post 2.96 EPS for the current fiscal year.

Corteva Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Shareholders of record on Monday, March 2nd will be paid a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.9%. The ex-dividend date is Monday, March 2nd. Corteva’s dividend payout ratio is currently 45.57%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Argus upgraded shares of Corteva to a “strong-buy” rating in a research note on Friday, January 16th. CICC Research upped their target price on shares of Corteva from $70.00 to $80.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. UBS Group cut shares of Corteva from a “buy” rating to a “hold” rating in a research report on Monday, February 9th. BNP Paribas Exane boosted their price target on shares of Corteva from $70.00 to $72.00 and gave the stock a “neutral” rating in a research note on Monday, November 17th. Finally, JPMorgan Chase & Co. cut Corteva from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $75.00 to $77.00 in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Corteva presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.30.

Read Our Latest Research Report on Corteva

Corteva Profile

(Free Report)

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

Featured Stories

Want to see what other hedge funds are holding CTVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corteva, Inc. (NYSE:CTVAFree Report).

Institutional Ownership by Quarter for Corteva (NYSE:CTVA)

Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.